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Abstract
Background: A decrease in the need for liver transplantations (LTX) in Primary Biliary Cirrhosis (PBC), possibly
related to treatment with ursodeoxycholic acid (UDCA), has been reported in the USA and UK. The aim of this
study was to assess LTX requirements in PBC over the past 20 years in the Netherlands.
Methods: Analysis of PBC transplant data of the Dutch Organ Transplant Registry during the period 1988-2008,
including both absolute and proportional numbers. The indication for LTX was categorized as liver failure,
hepatocellular carcinoma or poor quality of life (severe fatigue or pruritus). Data were analysed for two decades:
1.1.1988-31.12.1997 (1st) and 1.1.1998-31.12.2007 (2nd). The severity of disease was quantified using MELD scores. To
fit lines which show trends over time we applied a linear regression model.
Results: A total of 110 patients (87% women) was placed on the waiting list. 105 patients were transplanted (1st:
61, 2nd: 44), 5 (5%) died while listed. The absolute annual number of LTX for PBC slightly decreased during the
20 year period, the proportional number decreased significantly. At the time of LTX the mean age was 53.6 yrs.
(1st: 53.4, 2nd: 53.8), the mean MELD score 13.9 (1st:14.5, 2nd:13.0). The median interval from diagnosis to LTX was
90.5 months (1st:86.5, 2nd: 93.5). 69% of patients was treated with UDCA (1st 38%, 2nd 82%).
Conclusions: Over the past 20 years the absolute number of LTX for PBC in the Netherlands showed a tendency
to decrease whereas the proportional decrease was significant. There was a trend over time toward earlier
transplantation.
Background
In the past Primary Biliary Cirrhosis (PBC) was one of
the main indications for liver transplantation (LTX),
whereas nowadays, the proportion of patients receiving a
transplant for PBC has decreased to around 10% [1-3].
This could possibly be due to an increase in the number
of patients transplanted for other indications, to a
decrease in the need for transplantation in PBC or to a
combination of these factors. A decrease in need for LTX
in PBC could correspond with the finding of several
recent long-term cohort studies suggesting improved
transplantation-free survival for ursodeoxycholic acid
(UDCA) treated PBC patients, particularly for those with
a favorable biochemical response upon treatment [4-6].
The impression exists that in addition to a proportional
decrease in the need for LTX the absolute number of
patients with PBC receiving transplantation over time is
gradually falling. However, detailed reports on time
trends in the absolute number of LTX for PBC are sparse
[1,2]. We aimed to describe transplant patterns for PBC
and changes over the past 20 years in the Netherlands.
Methods
We performed a retrospective analysis of all patients who
underwent LTX in the Netherlands in the period
01.01.1988 until 31.12.2007. Only first liver transplanta-
tions were included for analysis. Patients who were listed
and/or transplanted during this period were identified
using the Dutch Organ Transplant Registry (NOTR).
Name, date of birth, indication and date of LTX were
obtained from this database. Additional individual data
were extracted from medical records in the 3 liver trans-
plant centers in the Netherlands: the University Medical
Centers in Groningen, Leiden and Rotterdam. NOTR and
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the liver transplantation centers gave permission to pub-
lish these data.
Laboratory data collected included alkaline phospha-
tase (ALP), aspartate aminotransferase (AST), alanine
aminotransferase (ALT), bilirubin, albumin and creatinin
levels, and platelet count, prothrombin time and INR, at
the time of PBC diagnosis, at the time of placement on
the waiting list and at the time of surgery. Most labora-
tory parameters were reported as the ratio of the test
result to the upper or lower limit of normal (ULN,
LLN) for the laboratory performing the test.
Definitions and statistical analysis
A definite diagnosis of PBC was made in the presence of 2
major plus 2 minor criteria or 1 major plus 4 minor cri-
teria. Major criteria were AMA titer ≥1:20 and compatible
liver biopsy, minor criteria were pruritus, jaundice, ALP
≥2-fold the upper limit of normal, serum IgM >2.8 g/l and
a positive Schirmer test (test to assess tear production) [7].
We divided the time span into the decades 1.1.1988-
31.12.1997 and 1.1.1998-31.12.2007. Based on serum bilir-
ubin, INR and creatinin the UNOS MELD score (Model
for End-Stage Liver Disease, http://www.mayoclinic.org/
meld/mayomodel6.html) was calculated. This model is
widely used to determine prognosis in patients with liver
disease [8,9]. In the Netherlands the MELD score is
used for stratifying patients and allocating organs since
December 2006. In addition, the disease was classified
based on serum albumin and bilirubin levels, resulting in
classes of early (both parameters normal), moderately
advanced (one parameter normal, one abnormal) and
advanced (both parameters abnormal) PBC [5]. Particu-
larly for patients transplanted in the first decade reliable
data on edema were not uniformly available, precluding
calculation of the Mayo Risk Score [10].
Serum bilirubin and/or albumin concentrations were
not available for 28 patients at the time of diagnosis but
were complete at the time of placement on the waiting
list and at the time of surgery. At the time of diagnosis
the MELD score could be calculated for 40 patients.
However, data were available for all patients at the time
of listing and transplantation.
The indications for liver transplantation were divided
into three subgroups: 1. liver failure including treat-
ment-resistant ascites and spontaneous bacterial perito-
nitis, recurrent variceal bleeding, progressive muscle
wasting and encephalopathy, 2. hepatocellular carcinoma
and 3. poor quality of life due to intractable pruritus or
severe chronic fatigue.
UDCA-treatment was classified as “yes” if the patient had
used 13-15 mg/kg/day UDCA for at least 2 years, as “no” if
UDCA was never used or for a period less than 2 years.
Linear regression models were applied to fit lines
which show trends over time for the number of LTX,
severity of disease and age at the time of LTX. A P
value of less than .05 was considered significant.
Results
Patients
Baseline patient characteristics are summarized in Table
1.
In total 105 PBC patients had a first liver transplant
during the study period, eighty-eight percent was female;
the mean age at the time of LTX was 53.6 years. The
median time from PBC diagnosis to the moment of
LTX was 90.5 months; the median time on the waiting
list was 4.1 months.
Changes in transplantation patterns over time
In the first decade (1.1.1988-31.12.1997) 61 PBC patients
were transplanted compared to 44 patients in the sec-
ond decade (1.1.1998-31.12.2007). In the first decade
PBC was the cause of liver disease in 11.7% of indivi-
duals undergoing transplantation compared to 4.5% in
the second decade.
Figure 1 visualizes a trend to a decrease in the absolute
numbers of LTX for PBC, including 5 patients who died
on the waiting list (p = 0.17), the proportional decrease is
significant (p < 0.001) (figure 2). As shown in table 1, the
age of patients at the time of PBC diagnosis, listing and
transplantation was comparable for the two decades.
Bilirubin and ALP levels were lower in the second
decade both at the time of PBC diagnosis and at the
time of listing and surgery. Also, the MELD scores and
the proportion of patients with advanced PBC at the
time of transplantation decreased over time, p = 0.14
and p = 0.03 respectively (trend-test).
The median interval from PBC diagnosis to the
moment of LTX was 86.5 months in the first decade,
and 93.5 months in the second decade. The median
time on the waiting list was 2.3 months and 8.5 months,
respectively.
LTX & indication
The indication for LTX was liver failure in 97 (92%)
cases (figure 1). 1 (1%) patient underwent liver trans-
plantation for the presence of hepatocellular carcinoma
and 7 (7%) patients for poor quality of life due to fatigue
or pruritus. In the latter group, the mean age at the
time of LTX was 48.3 years, the median interval
between diagnosis and transplantation was 58.8 months,
and the median time on the waiting list was 6.0 months.
6/7 (86%) of patients grafted for poor quality of life
were transplanted early in the second decade (figure 1).
Mortality on the waiting list
In total, 5/110 (5%) patients (4 female) died on the liver
transplant waiting list. Their mean age at the time of listing
Kuiper et al. BMC Gastroenterology 2010, 10:144
http://www.biomedcentral.com/1471-230X/10/144
Page 2 of 5
Table 1 Details of patients at the time of PBC diagnosis, placement on the waiting list and transplantation
PBC diagnosis Waiting list Transplantation
1st decade 2nd decade 1st decade 2nd decade 1st decade 2nd decade
1988-1997 1998-2008 1988-1997 1998-2008 1988-1997 1998-2008
Age (mean ± SD) 45.4 ± 7.2 45.4 ± 7.6 53.1 ± 7.6 53.0 ± 7.1 53.4 ± 7.6 53.8 ± 7.2
Female n (%) 56 (92) 36 (81) 56 (92) 36 (81) 56 (92) 36 (81)
UDCA n (%) 23 (38) started 36 (82) started 23 (38) 36 (82) 23 (38) 36 (82)
Bilirubin (ULN) 1.4(0.2-16.1)*) 1.0(0.4-6.6)*) 6.3(0.5-37.7)*) 3.6(0.5-29.6)*) 7.4 (0.4-37.7) 6.4 (0.5-43.1)
Albumin (LLN) 1.1 (0.7-2.6) 1.1 (0.8-2.0) 0.8 (0.5-6.5) 0.9 (0.6-1.2) 0.8 (0.5-6.5) 0.9 (0.3-1.3)
ALP (ULN) 5.0(1.1-19.4)*) 4.3(1.1-9.1)*) 4.5 (0.4-14.5) 2.8 (0.4-16.2) 4.1(0.4-12.6)#) 2.3(0.2-7.9)#)
AST (ULN) 2.4 (0.6-8.9) 2.1 (0.6-10.8) 3.3 (0.6-8.9) 2.8 (0.6-14.7) 2.9 (0.5-26.3) 3.0 (0.8-19.4)
ALT (ULN) 3.3 (0.7-9.3) 2.7 (0.9-14.3) 2.4 (0.4-9.3) 2.3 (0.6-12.8) 2.5 (0.2-14.6) 2.4 (0.4-18.2)
Creatinin (ULN) 0.6 (0.5-0.8) 0.7 (0.5-1.3) 0.7 (0.1-1.6) 0.7 (0.4-2.5) 0.7 (0.1-1.6) 0.7 (0.5-2.7)
INR 0.9(0.7-1.9)*) 0.8(0.6-1.0)*) 1.0 (0.7-2.4) 1.0 (0.7-1.7) 1.1 (0.7-2.8) 1.0 (0.7-2.2)
MELD (mean ± SD) 7.3 ± 2.7 7.0 ± 2.1 12.4 ± 5.1*) 14.5 ± 6.0*) 14.5 ± 6.0 13.0 ± 6.6
Prognostic class n (%)
Early 11 (18) 18 (41) 0 (0) 3 (7) 2 (3) 4 (9)
Moderately advanced 26 (43) 7 (16) 12(20) 11 (25) 8 (13) 11 (25)
Advanced 11 (18) 10 (23) 49 (80) 30 (68) 51 (84) 29 (66)
Insufficient data 13 (21) 9 (20) 0 (0) 0 (0) 0 (0) 0 (0)
*(p < 0.05 bold) p < 0.001
Laboratory values are expressed as the median of the number of times the upper or lower limit of normal (range between brackets).
Figure 1 Indications, waiting list mortality and annual absolute number of first-time liver transplantations for PBC in the Netherlands
from 1988 to 2008. The linear interpolation line indicates a decrease over time.
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was 55.4 years, the mean MELD score was 11.3 and the
median time from listing to death was 4.9 months. All
deaths occurred between 1998 and 2008, corresponding
with 10% (5/49) waiting list mortality in that period. Causes
of death were liver failure in 4 cases and heart failure in 1.
UDCA Treatment
In the first decade 38% of patients listed for transplanta-
tion had been treated with UDCA for at least 2 years
versus 82% in the second decade.
For the total group of patients the (mean) time they
had been treated with UDCA increased from 21.5
months in the first decade to 71.1 months in the second
decade. The mean duration of UDCA treatment for the
entire period analyzed was 42.3 months.
Discussion
The results of this study show that both the absolute and
the relative number of patients who received a liver
transplantation for the indication PBC has fallen during
the past 20 years in the Netherlands. The severity of dis-
ease at the time of transplantation, as indicated by serum
levels of bilirubin and albumin and by MELD scores,
slightly decreased while the age of the patients at the
time of listing and transplantation remained unchanged.
Our results are in agreement with a recent study from
the USA [1]. From 1995 to 2006 the authors observed a
significant decrease in the need for liver transplantation
in PBC while the total number of transplantations
increased and the number of transplantations for
another chronic cholestatic liver disease, namely PSC,
remained stable. The introduction of UDCA as standard
therapy of PBC was considered the most likely explana-
tion for the observed decline. Our data are also compa-
tible with a single center study from Birmingham UK,
reporting a decrease in the absolute and proportional
number of transplantations for PBC between 1983 and
1999. The authors also noted less advanced disease at
the time of transplantation for PBC over time [2]. We
cannot confirm another finding of this study, namely
that the age of patients at the moment of transplanta-
tion tends to increase.
A possible explanation for our findings remains uncer-
tain. Obviously, the actual number of liver transplantations
for PBC is influenced by numerous complex factors
including the incidence and natural history of the disease
over time, the availability of effective medical treatment,
referral patterns, selection criteria and the availability of
donor organs. The incidence of PBC in our country has
not been defined and therefore the potential importance
Figure 2 Annual absolute number of first-time liver transplantations for PBC versus proportional number in the Netherlands from
1988 to 2008. The linear interpolation lines indicate a decrease over time.
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of changes in time cannot be addressed properly.
A noticeable increased incidence of PBC has been
documented in the UK while other data suggest that the
incidence worldwide at least seems stable but may be
increasing [11,12]. If this also applies to our country an
increase or stable number of transplantations - and not a
decrease - would have been more likely. It has been estab-
lished that ursodeoxycholic acid has a beneficial effect in
PBC and may improve prognosis, in particular in cases
showing a clear biochemical response to treatment [5].
Given the almost uniform treatment of PBC with UDCA
during the last 10-15 years in the Netherlands, the use of
UDCA could well be a factor contributing to the observed
changes. However, it is obvious that the present study was
neither designed nor suitable to adequately assess the effi-
cacy of UDCA in PBC. In the absence of data on possible
changes in referral patterns for liver transplantation the
significance of this factor remains unknown. With respect
to selection criteria in general there was a change over
time towards acceptance of older patients. However, our
data show that the age at the time of listing and at the
time of surgery in PBC patients in fact did not change dur-
ing the 20 year study period, similar to findings in the
USA [1]. Only few individuals were transplanted for other
indications than liver failure, and thus changes in selection
criteria are not likely to be involved in the observed trend
toward less transplantation for PBC.
This was a retrospective study and the absolute num-
ber of patients was limited. We recognize that we were
unable to assess all potential factors influencing the
need and actual number of liver transplantations per-
formed in the Netherlands. On the other hand we
included all patients listed and/or transplanted for PBC
in our country and were able to collect and analyze rele-
vant detailed data for all cases.
Conclusions
Our study indicates that both the absolute and the relative
number of liver transplantations for PBC tended to
decrease during the past two decades. The general intro-
duction of UDCA as the standard treatment for PBC may
be a factor explaining this trend over time. However, other
mechanisms could well be involved given the many com-
plex factors determining the eventual number of patients
referred for, and finally undergoing, transplantation.
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